Esketamine for depression: all studies (page 15)

Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study.

Journal of Affective Disorders January 21, 2026 Jan Sarlon, Deanne Thomi, Annette B Brühl et al. 1 citation

Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...

DOI: 10.1016/j.jad.2026.121208 Full text Esketamine Mdd Treatment-resistant depression Intranasal racemic ketamine +1

Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine

BMC Psychiatry January 4, 2026 Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson et al. 2 citations

Abstract Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation...

DOI: 10.1186/s12888-025-07485-w Full text Treatment-resistant depression Major depressive disorder Esketamine Antidepressants +1

Clinician-patient communication in esketamine and psychedelic-assisted treatments for depression: a scoping review of evidence, gaps, and clinical implications

2026 Vassilis Martiadis, Fabiola Raffone, Domenico de Berardis

BACKGROUND: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and represents a critical clinical challenge. Esketamine (S-ketamine, Spravato), approved by FDA and EMA since 2019, and psychedelic-assisted therapies (psilocybin, MDMA) share a pharmacological feature unique among approved psychiatric treatments: they induce altered...

DOI: 10.17605/osf.io/kw4tv

Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients.

Frontiers in Medicine 2026 Hui Zhang, Yan An Jiang, Huajun Fu et al.

Postpartum depression (PPD) affects 10-20% of women after childbirth, with incidence reaching 30-50% in high-risk populations. Acute postoperative pain and sleep disturbance represent modifiable risk factors. This study evaluated whether a multimodal analgesic protocol combining dexmedetomidine and esketamine is associated with reduced PPD incidence in high-risk parturients undergoing cesarean...

DOI: 10.3389/fmed.2026.1828838 Full text Esketamine Cesarean delivery Dexmedetomidine High-risk parturients +3

Investigation of Esketamine Administration During Surgical Procedures for the Alleviation of Postoperative Anxiety and Depression in Adolescent Patients: A Randomized Controlled Trial.

Drug Design, Development and Therapy 2026 Yanhong Li, Kuangyu Zhao, Peipei Cao et al.

Surgical stress can lead to postoperative anxiety and depression, especially in adolescents. These complications reduce quality of life and increase medical burdens, but perioperative psychological interventions for adolescents are limited, and related mechanisms remain unclear. Esketamine (S-ketamine), an N-methyl-D-aspartate receptor (NMDAR) antagonist, has analgesic, sedative,...

DOI: 10.2147/dddt.s587626 Full text S-ketamine Inflammatory markers Postoperative pain

Bolus versus Continuous Infusion of Esketamine for Prevention of Postpartum Depression After Caesarean Delivery: A Randomized, Double-Blind, Controlled Trial.

Drug Design, Development and Therapy 2026 Jie Yang, Qiqi Yan, Ting Zhang et al.

Esketamine is increasingly being applied for preventing postpartum depression (PPD). However, clinical protocols for this application are inconsistent, particularly concerning the route of administration. The aim was to determine whether esketamine bolus administration differed from continuous infusion in terms of preventing PPD. A total of 503 subjects without prenatal depression undergoing...

DOI: 10.2147/dddt.s601347 Full text Esketamine Administration route Caesarean section Postpartum depression

Mental health professionals' perspective on the use of esketamine in treatment-resistant depression and their motivation to adopt it: a Saudi cross-sectional study.

Frontiers in Psychiatry 2026 Ahmad H Almadani, Ayedh H Alghamdi, Gosay M Almazyad et al.

Esketamine is an innovative treatment for individuals with treatment-resistant depression (TRD). However, its adoption could depend on the perceptions and motivations of prescribing psychiatrists, among other factors. This study aims to explore the attitudes of psychiatrists (of all levels, including those in training) across Saudi Arabia toward the use of esketamine for TRD and investigate the...

DOI: 10.3389/fpsyt.2026.1726411 Full text Esketamine Treatment-resistant depression Saudi arabia Attitudes +1

Single low-dose esketamine improves postpartum depression symptoms and recovery quality in cesarean section women.

American Journal of Translational Research 2026 Ran Jing, Yuanyan Tu

To investigate the effects of single low-dose esketamine combined with patient-controlled intravenous analgesia (PCIA) on early postpartum depression symptoms and recovery quality in women undergoing cesarean section. This prospective, randomized, controlled study enrolled 136 women scheduled for elective cesarean section, who were randomly assigned in a 1:1 ratio to the study group (esketamine...

DOI: 10.62347/euok7911 Full text Esketamine Low dose Cesarean section Patient-controlled intravenous analgesia +1

Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.

General Hospital Psychiatry 2026 Gabrielle F. M. Lovell, Shreya Vasudeva, Diana Orsini et al.

Ketamine is a dissociative anesthetic with potential for treating mood, anxiety, and related disorders; however, concerns have emerged regarding hepatotoxicity in the context of chronic treatment. Systematic searches of PubMed, Scopus, and Ovid databases were conducted from inception to August 2025. Eligible studies included randomized controlled trials (RCTs), observational studies, and case...

DOI: 10.1016/j.genhosppsych.2026.04.005 Full text Esketamine Major depressive disorder Alanine aminotransferase Aspartate aminotransferase +2

Esketamine ameliorates depression-like behavior in mice via modulation of the NRG1-ErbB4 pathway.

Frontiers in Psychiatry 2026 Hang Yu, Yuqiong Zhu, Jie Wang et al.

Esketamine has a significant and rapid antidepressant effect. Although studies have shown that Neuregulin 1 (NRG1) and it's signaling pathway are associated with depression, the possible regulatory relationship of esketamine on the NRG1-ErbB4 pathway is not yet clear. To induce depressive-like behavior in mice, a Chronic Social Defeat Stress (CSDS) model was established. Behavioral indicators...

DOI: 10.3389/fpsyt.2026.1722336 Full text Esketamine Erbb4 Nrg1 Depression disorder